跳转到主要内容
搜索
网络研讨会点播

模型引导的药物开发（MIDD）的监管环境演变：ICH M15 指南草案的影响

This webinar discusses the draft ICH M15 guidance. For the latest perspectives aligned with the final approved guidance, explore our updated webinar and readiness resources.

演讲嘉宾：

Hannah Jones
Hannah Jones

SVP, PBPK Consultancy Services, Certara

Rik de Greef
Dr. Rik de Greef

SVP, Quantitative Science Services, Certara

Dr. Krithika Shetty

Sr. Director, Clinical Pharmacology, Certara

Dr. Eva Gil Berglund

Sr. Director, Regulatory Strategy, Certara

ICH M15 Scorecard App
How ready is your MIDD strategy for ICH M15?

Get instant insights with our free interactive MIDD scorecard

Start your ICH M15 readiness assessment

精选推荐

The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators
The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with RegulatorsOn-Demand Webinar

The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development
ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug DevelopmentBlog

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug DevelopmentBlog

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

沪ICP备2022021526号
Powered by Translations.com GlobalLink Web Software